Relaxing incisions reduce postop astigmatism

Article

Relaxing incisions are a safe and effective method for reducing postoperative astigmatism and help improve visual acuity (VA), according to a study published in the March issue of the Journal of Refractive Surgery.

Relaxing incisions are a safe and effective method for reducing postoperative astigmatism and help improve visual acuity (VA), according to a study published in the March issue of the Journal of Refractive Surgery.

Margareta Claesson, MD and John Armitage, PhD, from the Sahlgrenska University Hospital, Sweden and the University of Bristol, UK, respectively, conducted a study to determine the impact of relaxing incisions for correcting postoperative astigmatism following penetrating keratoplasty.

Data was collected through the Swedish Corneal Transplant Register and, of the 1,161 grafts with complete two-year follow-up, 131 underwent relaxing incisions. Stepwise multiple regression was used to determine the factors that influenced the extent of astigmatism. The change in astigmatism brought about by relaxing incisions was evaluated by subtraction and vector analysis.

In patients who underwent relaxing incisions, astigmatism was reduced from 8.40 D to 3.80 D. The mean difference by subtraction was 4.50 D and vector analysis showed the overall reduction of astigmatism induced by surgery to be 7.90 D. Compared with grafts with no refractive surgery, a trend was seen that suggested corrected VA was improved following relaxing incisions.

It was concluded that relaxing incisions are safe and effective as a method of reducing postoperative astigmatism and may even help improve VA in some cases.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.